Replication of a neuroimaging biomarker for striatal dysfunction in psychosis.

Autor:	Rubio JM; Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA.; Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA.; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA., Lencz T; Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA.; Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA.; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA., Cao H; Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA.; Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA.; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA., Kraguljac N; Department of Psychiatry and Behavioral Health, The Ohio State University, Columbus, Ohio., Dhamala E; Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA.; Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA.; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA., Homan P; Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich, 8032, Zurich, Switzerland.; Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, 8057, Zurich, Switzerland., Horga G; Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, USA., Sarpal DK; Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Argyelan M; Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA.; Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA.; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA., Gallego J; Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA.; Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA.; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA., Cholewa J; Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA.; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA., Barber A; Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA.; Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA.; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA., Kane J; Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA.; Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA.; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA., Malhotra A; Donald and Barbara Zucker School of Medicine at Hofstra University - Northwell Health, New York, USA.; Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, New York, USA.; Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, New York, USA.
Jazyk:	angličtina
Zdroj:	MedRxiv : the preprint server for health sciences [medRxiv] 2023 Jul 23. Date of Electronic Publication: 2023 Jul 23.
DOI:	10.1101/2023.07.17.23292779
Abstrakt:	To bring biomarkers closer to clinical application, they should be generalizable, reliable, and maintain performance within the constraints of routine clinical conditions. The functional striatal abnormalities (FSA), is among the most advanced neuroimaging biomarkers in schizophrenia, trained to discriminate diagnosis, with post-hoc analyses indicating prognostic properties. Here, we attempt to replicate its diagnostic capabilities measured by the area under the curve (AUC) in receiver operator characteristic curves discriminating individuals with psychosis (n=101) from healthy controls (n=51) in the Human Connectome Project for Early Psychosis. We also measured the test-retest (run 1 vs 2) and phase encoding direction (i.e., AP vs PA) reliability with intraclass correlation coefficients (ICC). Additionally, we measured effects of scan length on classification accuracy (i.e., AUCs) and reliability (i.e., ICCs). Finally, we tested the prognostic capability of the FSA by the correlation between baseline scores and symptom improvement over 12 weeks of antipsychotic treatment in a separate cohort (n=97). Similar analyses were conducted for the Yeo networks intrinsic connectivity as a reference. The FSA had good/excellent diagnostic discrimination (AUC=75.4%, 95%CI=67.0%-83.3%; in non-affective psychosis AUC=80.5%, 95%CI=72.1-88.0%, and in affective psychosis AUC=58.7%, 95%CI=44.2-72.0%). Test-retest reliability ranged between ICC=0.48 (95%CI=0.35-0.59) and ICC=0.22 (95%CI=0.06-0.36), which was comparable to that of networks intrinsic connectivity. Phase encoding direction reliability for the FSA was ICC=0.51 (95%CI=0.42-0.59), generally lower than for networks intrinsic connectivity. By increasing scan length from 2 to 10 minutes, diagnostic classification of the FSA increased from AUC=71.7% (95%CI=63.1%-80.3%) to 75.4% (95%CI=67.0%-83.3%) and phase encoding direction reliability from ICC=0.29 (95%CI=0.14-0.43) to ICC=0.51 (95%CI=0.42-0.59). FSA scores did not correlate with symptom improvement. These results reassure that the FSA is a generalizable diagnostic - but not prognostic - biomarker. Given the replicable results of the FSA as a diagnostic biomarker trained on case-control datasets, next the development of prognostic biomarkers should be on treatment-response data. Competing Interests: Conflict of interest: JR has received research support from Alkermes, speaker bureau or advisory board compensation from TEVA, Karuna, Janssen, royalties from UpToDate. PH has received grants and honoraria from Novartis, Lundbeck, Mepha, Janssen, Boehringer Ingelheim, Neurolite outside of this work. JK has received funds for research support from H. Lundbeck, Janssen, and Otsuka; has received consulting fees or honoraria for lectures from Alkermes, Biogen, Boehringer Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HLS, Indivior, Intra-Cellular Therapies, Janssen, Johnson and Johnson, Karuna, LB Pharmaceuticals, Merck, Minerva, Neurocrine, Neumora, Newron, Novartis, Otsuka, Reviva, Roche, Saladax, Sunovion, Takeda, and Teva; and has ownership interest in HealthRhythms, North Shore Therapies, LB Pharmaceuticals, Medincell, and the Vanguard Research Group. The rest of the authors declare no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu